Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$42.43 - $70.83 $3.55 Million - $5.93 Million
83,700 Added 812.62%
94,000 $6.4 Million
Q2 2024

Aug 13, 2024

SELL
$41.33 - $74.26 $1.3 Million - $2.33 Million
-31,400 Reduced 75.3%
10,300 $435,000
Q1 2024

May 09, 2024

BUY
$56.27 - $73.77 $2.35 Million - $3.08 Million
41,700 New
41,700 $2.88 Million
Q3 2020

Nov 13, 2020

SELL
$72.92 - $102.01 $291,680 - $408,040
-4,000 Reduced 4.04%
94,900 $9.68 Million
Q2 2020

Aug 12, 2020

BUY
$55.75 - $92.75 $5.51 Million - $9.17 Million
98,900 New
98,900 $8.6 Million
Q4 2019

Feb 14, 2020

SELL
$77.66 - $99.74 $10.5 Million - $13.5 Million
-135,300 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$90.37 - $122.49 $2.2 Million - $2.98 Million
24,300 Added 21.89%
135,300 $12.2 Million
Q2 2019

Aug 12, 2019

BUY
$89.51 - $118.04 $5.76 Million - $7.59 Million
64,300 Added 137.69%
111,000 $13.1 Million
Q1 2019

May 10, 2019

BUY
$61.98 - $96.5 $799,542 - $1.24 Million
12,900 Added 38.17%
46,700 $4.05 Million
Q4 2018

Feb 13, 2019

SELL
$56.04 - $82.66 $3.72 Million - $5.48 Million
-66,300 Reduced 66.23%
33,800 $2.13 Million
Q3 2018

Nov 09, 2018

BUY
$48.29 - $80.6 $111,067 - $185,380
2,300 Added 2.35%
100,100 $7.9 Million
Q2 2018

Aug 08, 2018

BUY
$37.84 - $69.96 $1.04 Million - $1.92 Million
27,400 Added 38.92%
97,800 $5.85 Million
Q1 2018

May 09, 2018

BUY
$39.82 - $57.53 $1.16 Million - $1.67 Million
29,100 Added 70.46%
70,400 $2.84 Million
Q4 2017

Feb 09, 2018

BUY
$46.49 - $60.51 $1.06 Million - $1.38 Million
22,800 Added 123.24%
41,300 $2.17 Million
Q3 2017

Nov 13, 2017

BUY
$37.05 - $47.12 $685,425 - $871,720
18,500
18,500 $872,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.7B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Twin Tree Management, LP Portfolio

Follow Twin Tree Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Twin Tree Management, LP with notifications on news.